IDEAYA Biosciences

IDEAYA Biosciences

IDYA
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

IDYA · Stock Price

USD 28.24+10.82 (+62.11%)
Market Cap: $2.5B

Historical price data

Market Cap: $2.5BPipeline: 8 drugs (2 Phase 3)Patents: 12Founded: 2016HQ: South San Francisco, United States

Overview

IDEAYA Biosciences is a precision medicine oncology company founded in 2016 with a mission to develop transformative, biomarker-selected cancer therapies. It has established itself as a leader in the field of synthetic lethality, building a robust clinical-stage pipeline through internal discovery and strategic collaborations with major pharmaceutical partners like GSK, Pfizer, and Gilead. The company's strategy focuses on exploiting specific genetic vulnerabilities in cancer cells to achieve a therapeutic window, with its most advanced programs targeting MTAP-deleted solid tumors, GNAQ/GNA11-mutant cancers, and homologous recombination deficient tumors.

Oncology

Technology Platform

An integrated precision medicine platform centered on synthetic lethality, combining target & biomarker discovery, translational biology, and small molecule/protein degrader therapeutics to develop drugs for genetically defined cancer populations.

Pipeline

8
8 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
DarovasertibUveal MelanomaPhase 3
IDE196 + Crizotinib + Pembrolizumab + Ipilimumab + Nivolumab...Metastatic Uveal MelanomaPhase 2/3
DarovasertibUveal MelanomaPhase 2
IDE849 + durvalumab + IDE161Small-cell Lung CancerPhase 1/2
IDE196 + Binimetinib + CrizotinibMetastatic Uveal MelanomaPhase 1/2